Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Implications of race-neutral equations on interpretation of lung function in Australia.

Internal medicine journal·2026

Same author

Topical treatments and photodynamic therapy for actinic keratosis of the face and scalp.

The Cochrane database of systematic reviews·2026

Same author

Childhood Pulmonary Virus Infection and Future Bronchiectasis.

Archivos de bronconeumologia·2025

Same author

Pirfenidone Mitigates Transforming Growth Factor-β-induced Inflammation after Viral Infection.

American journal of respiratory cell and molecular biology·2025

Same author

Impaired diffusing capacity and COPD incidence in adults with symptoms and normal spirometry.

Respiratory medicine·2024

Same author

Current physiotherapy practice for adults with bronchiectasis: Data from the Australian bronchiectasis registry.

Respiratory medicine·2024

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Lung diffusing capacity in adult bronchiectasis: a longitudinal study.

Paul T King¹, Stephen R Holdsworth, Nicholas J Freezer

¹Department of Respiratory and Sleep Medicine, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne 3168, Australia. paul.king@med.monash.edu.au

Respiratory Care

|December 3, 2010

Summary

This summary is machine-generated.

Adult bronchiectasis patients experience a progressive decline in lung diffusing capacity (D(LCO)). This decline in D(LCO) correlates with age and reduced FEV1, indicating worsening lung function over time.

More Related Videos

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Jun 6, 2026

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Area of Science:

Pulmonary Medicine
Respiratory Physiology

Background:

Bronchiectasis is associated with declining lung volumes.
Interstitial lung disease is a known feature of bronchiectasis.
The impact on diffusing capacity of the lung for carbon monoxide (D(LCO)) in bronchiectasis is not well understood.

Purpose of the Study:

To evaluate the longitudinal decline in D(LCO) in adult patients with bronchiectasis.
To investigate the relationship between D(LCO) decline and other clinical parameters.

Main Methods:

Sixty-one adult bronchiectasis patients underwent baseline assessment.
Regular clinical and lung function assessments were conducted over a median of 7 years.
Longitudinal changes in D(LCO) and D(LCO) adjusted for alveolar volume (D(LCO)/V(A)) were analyzed.

Main Results:

Patients had mild obstructive lung disease with normal baseline D(LCO).
An accelerated decline in D(LCO) (median 2.9%/year) and D(LCO)/V(A) (median 2.4%/year) was observed.
D(LCO) decline was significantly associated with patient age and decline in FEV1.

Conclusions:

Adult bronchiectasis is characterized by a progressive decline in D(LCO).
This decline suggests worsening gas exchange in patients with bronchiectasis over time.